Nektar enters quiet period ahead of REZOLVE-AA follow-up data
Nektar said its quiet period began Sept. 8, 2026, ahead of 24-week off-treatment follow-up data from the Phase 2b REZOLVE-AA study of rezpegaldesleukin.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.